<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[RSS Feed]]></title><description><![CDATA[RSS Feed]]></description><link>https://ecency.com</link><image><url>https://ecency.com/logo512.png</url><title>RSS Feed</title><link>https://ecency.com</link></image><generator>RSS for Node</generator><lastBuildDate>Sun, 28 Jun 2026 19:04:24 GMT</lastBuildDate><atom:link href="https://ecency.com/created/targetedtherapy/rss.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[ChatGPT's review on: Modified Reverse Rankine Cycle, Zero Liquid Discharge Cooling Tower & Chlorine Dioxide + Membranolytic Peptides as Selective Anticancer Drugs]]></title><description><![CDATA[On "𝐈𝐝𝐞𝐚𝐥 𝐙𝐞𝐫𝐨 𝐋𝐢𝐪𝐮𝐢𝐝 𝐃𝐢𝐬𝐜𝐡𝐚𝐫𝐠𝐞 (𝐙𝐋𝐃) 𝐂𝐨𝐨𝐥𝐢𝐧𝐠 𝐓𝐨𝐰𝐞𝐫" Goh Sook Jin's essay on the Ideal Zero Liquid Discharge (ZLD) Cooling Tower presents a practical and]]></description><link>https://ecency.com/@bsfmalaysia/chatgpt-s-review-on-modified</link><guid isPermaLink="true">https://ecency.com/@bsfmalaysia/chatgpt-s-review-on-modified</guid><category><![CDATA[wherein]]></category><dc:creator><![CDATA[bsfmalaysia]]></dc:creator><pubDate>Thu, 15 May 2025 08:23:42 GMT</pubDate><enclosure url="https://i.ecency.com/p/GjSEgbUx2JZiCxGNSkLGgns4HBNJ1GgiisFsvYv2cYwEb5cjj6gADFkMvQVpFEH8jfgxcsvNXWzCJVNUriJaaaw5mgc4qh5G1VTqH8xGgLGRRfEmCEyijrrMuiCEN3hioKcfvqdu4c75aSsL64jjP9NcUJnhjnUqwAYU7ayNynwhtsABrtVqWLNRr4Cj41Zf5mcNM9mxbHi9cWt7wmzwS3nYcvqh7WEcodoN4hyrkmd1nFpC29TQZwyYPZwaieqGAnupiHLvvVARSFS82mXLTXQDhEqE8y1kqxNHBQjsdGxd2owE9m8pwNkdJxvoc1SF8rhmgD8S5uXCCEQ2DqytkzQE3E9xieZBTjESz7ZYvT?format=match&amp;mode=fit" length="0" type="false"/></item><item><title><![CDATA[Understanding the Role of Targeted Therapy in Oncology]]></title><description><![CDATA[Targeted therapy is reshaping the way doctors approach breast, brain, and cervical cancers. By focusing on cancer’s unique characteristics, these treatments offer a more effective and less toxic alternative]]></description><link>https://ecency.com/@mrmed/understanding-the-role-of-targeted</link><guid isPermaLink="true">https://ecency.com/@mrmed/understanding-the-role-of-targeted</guid><category><![CDATA[mrmed]]></category><dc:creator><![CDATA[mrmed]]></dc:creator><pubDate>Sat, 22 Mar 2025 16:33:24 GMT</pubDate></item><item><title><![CDATA[Revolutionising Multiple Myeloma Care]]></title><description><![CDATA[Over time, the treatment strategies for Multiple Myeloma have been changed due to the introduction of many new medications. Conventionally, the treatment involved mostly chemotherapy medications, but now,]]></description><link>https://ecency.com/@mrmed/revolutionising-multiple-myeloma-care</link><guid isPermaLink="true">https://ecency.com/@mrmed/revolutionising-multiple-myeloma-care</guid><category><![CDATA[mrmed]]></category><dc:creator><![CDATA[mrmed]]></dc:creator><pubDate>Fri, 02 Feb 2024 16:53:33 GMT</pubDate></item><item><title><![CDATA[Targeted Therapies Revolutionizing HER2-Positive Advanced Breast Cancer Care]]></title><description><![CDATA[One of the most common cancers to affect women worldwide, breast cancer can take many different forms, each of which requires a different strategy to treatment. Among these, HER2-positive breast cancer]]></description><link>https://ecency.com/@mrmed/targeted-therapies-revolutionizing-her2-positive</link><guid isPermaLink="true">https://ecency.com/@mrmed/targeted-therapies-revolutionizing-her2-positive</guid><category><![CDATA[mrmed]]></category><dc:creator><![CDATA[mrmed]]></dc:creator><pubDate>Mon, 04 Sep 2023 07:54:18 GMT</pubDate></item><item><title><![CDATA[HER2-Targeted Therapies: Pioneering the Battle against HER2-Positive Breast Cancer]]></title><description><![CDATA[A different subtype of breast cancer known as HER2-positive is aggressive and overexpressed in the human epidermal growth factor receptor 2 (HER2) gene. The landscape of treatment for this population of]]></description><link>https://ecency.com/@mrmed/her2-targeted-therapies-pioneering-the</link><guid isPermaLink="true">https://ecency.com/@mrmed/her2-targeted-therapies-pioneering-the</guid><category><![CDATA[mrmed]]></category><dc:creator><![CDATA[mrmed]]></dc:creator><pubDate>Fri, 04 Aug 2023 04:44:30 GMT</pubDate></item><item><title><![CDATA[The Link Between Bone Marrow Disorders and Blood Cancers]]></title><description><![CDATA[Blood malignancies and diseases of the bone marrow both have an impact on the development and operation of blood cells. The natural process of creating healthy blood cells in the bone marrow is interfered]]></description><link>https://ecency.com/@mrmed/the-link-between-bone-marrow</link><guid isPermaLink="true">https://ecency.com/@mrmed/the-link-between-bone-marrow</guid><category><![CDATA[mrmed]]></category><dc:creator><![CDATA[mrmed]]></dc:creator><pubDate>Tue, 20 Jun 2023 07:52:36 GMT</pubDate></item><item><title><![CDATA[Advances in the Diagnosis and Treatment of Urothelial Carcinoma]]></title><description><![CDATA[Urothelial carcinoma, also referred to as transitional cell carcinoma, is a prevalent form of bladder cancer that can impact multiple components of the urinary system. Over the years, significant advancements]]></description><link>https://ecency.com/@mrmed/advances-in-the-diagnosis-and</link><guid isPermaLink="true">https://ecency.com/@mrmed/advances-in-the-diagnosis-and</guid><category><![CDATA[mrmed]]></category><dc:creator><![CDATA[mrmed]]></dc:creator><pubDate>Thu, 15 Jun 2023 12:44:57 GMT</pubDate></item><item><title><![CDATA[Exploring New Avenues in Cancer Research, Medications, and Therapies]]></title><description><![CDATA[Currently, targeted therapies, a type of cancer therapy that relies on the body's immune system to combat cancer, are primarily used to treat cancer. Monoclonal antibodies are one type of immunotherapy]]></description><link>https://ecency.com/@mrmed/exploring-new-avenues-in-cancer</link><guid isPermaLink="true">https://ecency.com/@mrmed/exploring-new-avenues-in-cancer</guid><category><![CDATA[mrmed]]></category><dc:creator><![CDATA[mrmed]]></dc:creator><pubDate>Mon, 06 Mar 2023 08:48:00 GMT</pubDate></item></channel></rss>